Breaking News Instant updates and real-time market news.

BSX

Boston Scientific

$35.88

0.95 (2.72%)

06:36
04/24/19
04/24
06:36
04/24/19
06:36

Boston Scientific sees Q2 adj. EPS 37c-39c, consensus 39c

Sees Q2 revenue up 5%-7% on a reported basis and a growth range of approximately 6%-7% on an organic basis. Q2 organic guidance excludes the impact of foreign currency fluctuations and contribution of approximately 140 basis points from the acquisitions of NxThera, Claret and Augmenix, each with no prior period related net sales.

  • 24

    Apr

  • 03

    May

  • 04

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 18

    May

  • 20

    May

  • 29

    May

  • 26

    Jun

  • 13

    Nov

BSX Boston Scientific
$35.88

0.95 (2.72%)

04/16/19
PIPR
04/16/19
NO CHANGE
Target $42
PIPR
Overweight
Boston Scientific selloff today a buying opportunity, says Piper Jaffray
04/16/19
PIPR
04/16/19
NO CHANGE
Target $42
PIPR
Overweight
Boston Scientific should be bought on surgical mesh selloff, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien recommends using the selloff today in shares of Boston Scientific after the FDA ordered all manufacturers of surgical mesh intended for transvaginal repair to stop selling and distributing their products immediately as a buying opportunity. Mesh products have been declining for several years at Boston Scientific and represented only ~1% of revenue in 2018, O'Brien tells investors in an intraday research note. The analyst estimates the company's revenue will be negatively impacted by less than $50M in 2019. Further, Boston Scientific is currently working with the FDA on a resolution, adds the analyst. Boston Scientific still has a "plethora of high-growth product launches fully intact" including Lotus, Acurate neo, and Watchman in Japan, "which should help cushion any lost revenue," says O'Brien. He has an Overweight rating on the shares with a $42 price target. The stock in afternoon trading is down 4% to $36.34.
04/16/19
WELS
04/16/19
NO CHANGE
WELS
Boston Scientific mesh sales impacted by FDA recall about $25M, says Wells Fargo
Wells Fargo analyst Larry Biegelsen says that Boston Scientific has informed him that total mesh sales are about $100M and that the products impacted by the FDA recall represent a subset of those sales or about $25M or 0.3% of total sales. The firm had previously stated that the mesh sales impacted by the FDA recall were about $100M in 2018. Biegelsen notes that the lower figure should be "more manageable" for the company. According to the analyst, Boston Scientific is surprised and disappointed by the FDA's decision, which impacts Uphold LITE Vaginal Support System and the Xenform Soft Tissue Repair Matrix for pelvic organ prolapse.
04/23/19
PIPR
04/23/19
NO CHANGE
Target $42
PIPR
Overweight
Boston Scientific Lotus approval may accelerate share gains, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien kept his Overweight rating and $42 price target on Boston Scientific after its "long anticipated" FDA approval of Lotus Edge transcatheter aortic valve replacement, or TAVR, product. The analyst believes that with the combination of differentiated features and the "buzz at previous medical conferences" about the relaunch may accelerate the company's market share capture in the TAVR space. O'Brien calls today's news a "strong positive" for the stock given the "recent transvaginal surgical mesh notice and paclitaxel concerns."

TODAY'S FREE FLY STORIES

CTSH

Cognizant

$62.55

0.92 (1.49%)

05:57
06/18/19
06/18
05:57
06/18/19
05:57
Hot Stocks
Cognizant to acquire Zenith Technologies, terms not disclosed »

Cognizant announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

AL

Air Lease

$38.66

-0.185 (-0.48%)

, BA

Boeing

$354.90

7.71 (2.22%)

05:56
06/18/19
06/18
05:56
06/18/19
05:56
Hot Stocks
Air Lease confirms lease placement of ten new Boeing 787-10 with Korean Air »

Air Lease (AL) announced…

AL

Air Lease

$38.66

-0.185 (-0.48%)

BA

Boeing

$354.90

7.71 (2.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 13

    Nov

BA

Boeing

$354.90

7.71 (2.22%)

, AL

Air Lease

$38.66

-0.185 (-0.48%)

05:54
06/18/19
06/18
05:54
06/18/19
05:54
Hot Stocks
Korean Air announces intent to acquire 30 787 Dreamliners »

Boeing (BA), Korean Air…

BA

Boeing

$354.90

7.71 (2.22%)

AL

Air Lease

$38.66

-0.185 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 13

    Nov

JKS

JinkoSolar

$22.59

-2.08 (-8.43%)

05:53
06/18/19
06/18
05:53
06/18/19
05:53
Downgrade
JinkoSolar rating change  »

JinkoSolar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

ORCL

Oracle

$53.10

-0.19 (-0.36%)

05:52
06/18/19
06/18
05:52
06/18/19
05:52
Downgrade
Oracle rating change  »

Oracle downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

TSN

Tyson Foods

$78.53

-3.4 (-4.15%)

, PPC

Pilgrim's Pride

$25.31

-0.98 (-3.73%)

05:51
06/18/19
06/18
05:51
06/18/19
05:51
Recommendations
Tyson Foods, Pilgrim's Pride, Sanderson Farms analyst commentary  »

Mizuho lowers near-term…

TSN

Tyson Foods

$78.53

-3.4 (-4.15%)

PPC

Pilgrim's Pride

$25.31

-0.98 (-3.73%)

SAFM

Sanderson Farms

$133.50

-10.73 (-7.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 20

    Jun

  • 13

    Nov

FB

Facebook

$188.89

7.54 (4.16%)

05:47
06/18/19
06/18
05:47
06/18/19
05:47
Hot Stocks
Facebook unveils blockchain currency Libra with plans to launch in 2020 »

Facebook announced on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

ES

Eversource

$76.49

-0.91 (-1.18%)

05:36
06/18/19
06/18
05:36
06/18/19
05:36
Recommendations
Eversource analyst commentary  »

Eversource price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STIM

Neuronetics

$11.41

-0.11 (-0.95%)

05:21
06/18/19
06/18
05:21
06/18/19
05:21
Recommendations
Neuronetics analyst commentary  »

Neuronetics reiterated as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGF.B

Lionsgate

$11.30

-0.04 (-0.35%)

, LGF

Use LGF.A, LGF.B

$0.00

(0.00%)

05:17
06/18/19
06/18
05:17
06/18/19
05:17
Recommendations
Lionsgate, Use LGF.A, LGF.B analyst commentary  »

Lionsgate price target…

LGF.B

Lionsgate

$11.30

-0.04 (-0.35%)

LGF

Use LGF.A, LGF.B

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRAY

ViewRay

$8.96

0.215 (2.46%)

05:14
06/18/19
06/18
05:14
06/18/19
05:14
Initiation
ViewRay initiated  »

ViewRay initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLAKY

Lufthansa

$0.00

(0.00%)

05:12
06/18/19
06/18
05:12
06/18/19
05:12
Downgrade
Lufthansa rating change  »

Lufthansa downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRZF

Evraz

$0.00

(0.00%)

05:11
06/18/19
06/18
05:11
06/18/19
05:11
Downgrade
Evraz rating change  »

Evraz downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRZF

Evraz

$0.00

(0.00%)

05:10
06/18/19
06/18
05:10
06/18/19
05:10
Downgrade
Evraz rating change  »

Evraz downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USM

U.S. Cellular

$44.15

0.375 (0.86%)

05:09
06/18/19
06/18
05:09
06/18/19
05:09
Upgrade
U.S. Cellular rating change  »

U.S. Cellular upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDS

Telephone and Data

$29.21

-0.11 (-0.38%)

05:08
06/18/19
06/18
05:08
06/18/19
05:08
Upgrade
Telephone and Data rating change  »

Telephone and Data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESS

Essex Property Trust

$302.21

3.03 (1.01%)

05:07
06/18/19
06/18
05:07
06/18/19
05:07
Downgrade
Essex Property Trust rating change  »

Essex Property Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 11

    Jul

CFPZF

Canfor

$0.00

(0.00%)

05:06
06/18/19
06/18
05:06
06/18/19
05:06
Upgrade
Canfor rating change  »

Canfor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFTBF

West Fraser Timber

$0.00

(0.00%)

05:05
06/18/19
06/18
05:05
06/18/19
05:05
Upgrade
West Fraser Timber rating change  »

West Fraser Timber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RFP

Resolute Forest

$6.12

0.015 (0.25%)

05:05
06/18/19
06/18
05:05
06/18/19
05:05
Upgrade
Resolute Forest rating change  »

Resolute Forest upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLAKY

Lufthansa

$0.00

(0.00%)

05:03
06/18/19
06/18
05:03
06/18/19
05:03
Downgrade
Lufthansa rating change  »

Lufthansa downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACCYY

Accor

$0.00

(0.00%)

05:02
06/18/19
06/18
05:02
06/18/19
05:02
Upgrade
Accor rating change  »

Accor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$42.65

0.19 (0.45%)

05:01
06/18/19
06/18
05:01
06/18/19
05:01
Downgrade
Sanofi rating change  »

Sanofi downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 16

    Sep

AXELF

Axel Springer

$0.00

(0.00%)

04:59
06/18/19
06/18
04:59
06/18/19
04:59
Downgrade
Axel Springer rating change  »

Axel Springer downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTSKY

Otsuka

$0.00

(0.00%)

04:58
06/18/19
06/18
04:58
06/18/19
04:58
Downgrade
Otsuka rating change  »

Otsuka downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.